ArticleFrontiers in cell and developmental biology2021
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 21 citations in OpenAlex.
- HDAC1 promotes lung adenocarcinoma progression via the nuclear accumulation of β‑catenin.Oncology reports · 2026Article
- Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax.Frontiers in oncology · 2026Article
- Development of PROTAC-Based Strategies for Cannabinoid Receptor Type 1 (CBACS pharmacology & translational science · 2025Article
- Diabetes is causally associated with increased breast cancer mortality by inducing FIBCD1 to activate MCM5-mediated cell cycle arrest via modulating H3K27ac.Cell death & disease · 2025Article
- Transcription factor E2F1 promotes non-small cell lung cancer progression by activating the PI3K/AKT pathway through MCM4.Journal of cardiothoracic surgery · 2025Article
- Mechanism of astragaloside A against lung adenocarcinoma based on network pharmacology combined with molecular dynamics simulation technique.Scientific reports · 2025Article
- TFAP4 Regulation of MCM5 Activates the PI3K/AKT Pathway to Promote Invasion and Metastasis of Gastric Cancer.Digestive diseases and sciences · 2025Article
- The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication.Translational cancer research · 2025Article
- USP5-dependent HDAC1 promotes cisplatin resistance and the malignant progression of non-small cell lung cancer by regulating RILP acetylation levels.Thoracic cancer · 2025Article
- HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing.Journal of translational medicine · 2024Article
- Research Progress on the Anti-Cancer Effects ofMolecules (Basel, Switzerland) · 2024Review
- Unwinding Helicase MCM Functionality for Diagnosis and Therapeutics of Replication Abnormalities Associated with Cancer: A Review.Molecular diagnosis & therapy · 2024Review
- Systematic analysis of expression and prognostic significance for MCM family in head and neck squamous cell carcinoma.Histology and histopathology · 2024Article
- MCM5 is a Novel Therapeutic Target for Glioblastoma.OncoTargets and therapy · 2024Article
- Enhanced MCM5 Level Predicts Bad Prognosis in Acute Myeloid Leukemia.Molecular biotechnology · 2023Article
- Phase separation of DDX21 promotes colorectal cancer metastasis via MCM5-dependent EMT pathway.Oncogene · 2023Article
- O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an NSignal transduction and targeted therapy · 2023Article
- MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.Frontiers in oncology · 2022Article
- Comprehensive analyses reveal the role of histone deacetylase genes in prognosis and immune response in low-grade glioma.PloS one · 2022Article
- The Potential Mechanism of HDAC1-Catalyzed Histone Crotonylation of Caspase-1 in Nonsmall Cell Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
- Retracted
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistone deacetylase 1 (HDAC1) is essential in the malignant progression of tumors. However, there is no obvious relationship between the expression of HDAC1 and the survival of lung cancer patients. Herein, we explored the involvement of minichromosome maintenance complex component 5 (MCM5) and HDAC1 interaction in the epithelial-to-mesenchymal transition (EMT)-dependent malignant progression of lung cancer.
methodsWe analyzed the expression of MCM5 and HDAC1 in The Cancer Genome Atlas database and clinical samples, as well as their impact on patient survival. Cell and animal experiments were performed to verify the promotion of EMT in lung cancer cells mediated by MCM5 and HDAC1.
resultsWe found that lung adenocarcinoma patients with high expression of MCM5 and HDAC1 had poor survival time. Overexpression of MCM5 and HDAC1 in A549 and H1975 cells can promote proliferation and invasion
conclusionThe interaction between MCM5 and HDAC1 aggravated the EMT-dependent malignant progression of lung cancer. Astragaloside IV can block the interaction between MCM5 and HDAC1 to inhibit the progression of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.